Search

Your search keyword '"De Canal, Gabriella"' showing total 24 results
Start Over Author "De Canal, Gabriella"
24 results on '"De Canal, Gabriella"'

1. BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases

Author

Carbo-Meix, Anna, primary, Guijarro, Francesca, additional, Wang, Luojun, additional, Grau, Marta, additional, Royo, Romina, additional, Frigola, Gerard, additional, Playa-Albinyana, Heribert, additional, Buhler, Marco M., additional, Clot, Guillem, additional, Duran-Ferrer, Marti, additional, Lu, Junyan, additional, Granada, Isabel, additional, Baptista, Maria-Joao, additional, Navarro, Jose-Tomas, additional, Espinet, Blanca, additional, Puiggros, Anna, additional, Tapia, Gustavo, additional, Bandiera, Laura, additional, De Canal, Gabriella, additional, Bonoldi, Emanuela, additional, Climent, Fina, additional, Ribera-Cortada, Inmaculada, additional, Fernandez-Caballero, Mariana, additional, De la Banda, Esmeralda, additional, Do Nascimento, Janilson, additional, Pineda, Alberto, additional, Vela, Dolors, additional, Rozman, Maria, additional, Aymerich, Marta, additional, Syrykh, Charlotte, additional, Brousset, Pierre, additional, Perera, Miguel, additional, Yanez, Lucrecia, additional, Ortin, Jesus Xavier, additional, Tuset, Esperanza, additional, Zenz, Thorsten, additional, Cook, James R., additional, Swerdlow, Steven H., additional, Martin-Subero, Jose I., additional, Colomer, Dolors, additional, Matutes, Estella, additional, Bea, Silvia, additional, Costa, Dolors, additional, Nadeu, Ferran, additional, and Campo, Elias, additional

Published
2023
Full Text
View/download PDF

2. Acute Promyelocytic Leukemia with del(6)(p22) and Atypical bcr2 PML::RARA Fusion Transcript: A Case Report

Author

Lauricella, Calogero, primary, Greco, Rosa, additional, Mancini, Valentina, additional, Motta, Valentina, additional, Ciraolo, Anna, additional, De Canal, Gabriella, additional, De Paoli, Elena, additional, Paglino, Giulia, additional, Guido, Valentina, additional, Bonoldi, Emanuela, additional, Veronese, Silvio, additional, and Soriani, Silvia, additional

Published
2022
Full Text
View/download PDF

3. Concomitant JAK2 V617F mutation and rare e1a2 BCR-ABL1 transcript isoform in a patient with myeloproliferative neoplasm

Author

Soriani, Silvia, primary, Lauricella, Calogero, additional, Frungillo, Niccolò, additional, De Troia, Beatrice Boido, additional, Motta, Valentina, additional, Cesana, Clara, additional, Guido, Valentina, additional, De Canal, Gabriella, additional, De Paoli, Elena, additional, Veronese, Silvio, additional, Bonoldi, Emanuela, additional, and Romitti, Lorenza, additional

Published
2022
Full Text
View/download PDF

4. Acute Promyelocytic Leukemia with del(6)(p22) and Atypical bcr2 PML::RARA Fusion Transcript: A Case Report.

Author

Lauricella, Calogero, Greco, Rosa, Mancini, Valentina, Motta, Valentina, Ciraolo, Anna, De Canal, Gabriella, De Paoli, Elena, Paglino, Giulia, Guido, Valentina, Bonoldi, Emanuela, Veronese, Silvio, and Soriani, Silvia

Subjects
ACUTE promyelocytic leukemia, ACUTE myeloid leukemia, GENE fusion, TRETINOIN, CHROMOSOMES
Abstract

More than 95% of patients with acute promyelocytic leukemia (APL) are characterized by the reciprocal translocation t(15;17)(q24;21), which involves the promyelocytic leukemia protein (PML) gene on chromosome 15 and the retinoic acid receptor-α (RARA) gene on chromosome 17, leading to the production of the PML::RARA chimeric gene. Additional chromosomal abnormalities are described in all acute myeloid leukemias and occur in approximately one-third of patients with newly diagnosed APL. Here, we report the case of de novo APL showing the classical t(15;17)(q24;q21), a deletion of the short arm of chromosome 6 (6p), and a noncanonical molecular variant of the PML::RARA transcript. Nevertheless, the patient achieved complete remission after treatment with conventional therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Notwithstanding that the molecular pathogenesis of this type of atypical variant still remains unknown, we conclude that this atypical PML::RARA bcr2 fusion gene associated with del(6p) does not seem to alter the effectiveness of combined treatment with ATRA and ATO. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

5. Nilotinib‐induced bone marrow CD34+/lin‐Ph+ cells early clearance in newly diagnosed CP‐Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study

Author

Pungolino, Ester, primary, D'adda, Mariella, additional, De Canal, Gabriella, additional, Trojani, Alessandra, additional, Perego, Alessandra, additional, Elena, Chiara, additional, Lunghi, Francesca, additional, Turrini, Mauro, additional, Borin, Lorenza, additional, Iurlo, Alessandra, additional, Latargia, Maria Luisa, additional, Carraro, Maria Cristina, additional, Spina, Francesco, additional, Artale, Salvatore, additional, Anghilieri, Michela, additional, Molteni, Alfredo, additional, Caramella, Marianna, additional, Baruzzo, Giacomo, additional, Nichelatti, Michele, additional, Di Camillo, Barbara, additional, and Cairoli, Roberto, additional

Published
2021
Full Text
View/download PDF

6. BCR/ABL1 Fluorescence In Situ Hybridization Fusion Signals on Both Copies of Chromosome 22 in a Philadelphia-Masked Chronic Myeloid Leukemia Case: Implication for the Therapy

Author

Soriani, Silvia, primary, Guido, Valentina, additional, Bertani, Giambattista, additional, Cesana, Clara, additional, Motta, Valentina, additional, De Canal, Gabriella, additional, De Paoli, Elena, additional, Veronese, Silvio, additional, Bonoldi, Emanuela, additional, and Romitti, Lorenza, additional

Published
2021
Full Text
View/download PDF

7. Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects

Author

Trojani, Alessandra, primary, Pungolino, Ester, additional, Rossi, Giuseppe, additional, D'adda, Mariella, additional, Bossi, Luca Emanuele, additional, Baruzzo, Giacomo, additional, Di Camillo, Barbara, additional, Perego, Alessandra, additional, Turrini, Mauro, additional, Elena, Chiara, additional, Borin, Lorenza Maria, additional, Iurlo, Alessandra, additional, Malato, Simona, additional, Spina, Francesco, additional, Latargia, Maria Luisa, additional, Spedini, Pierangelo, additional, Artale, Salvatore, additional, Anghilieri, Michela, additional, Carraro, Maria Cristina, additional, Bucelli, Cristina, additional, De Canal, Gabriella, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2019
Full Text
View/download PDF

9. Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment

Author

Trojani, Alessandra, primary, Pungolino, Ester, additional, Dal Molin, Alessandra, additional, Lodola, Milena, additional, Rossi, Giuseppe, additional, D’Adda, Mariella, additional, Perego, Alessandra, additional, Elena, Chiara, additional, Turrini, Mauro, additional, Borin, Lorenza, additional, Bucelli, Cristina, additional, Malato, Simona, additional, Carraro, Maria Cristina, additional, Spina, Francesco, additional, Latargia, Maria Luisa, additional, Artale, Salvatore, additional, Spedini, Pierangelo, additional, Anghilieri, Michela, additional, Di Camillo, Barbara, additional, Baruzzo, Giacomo, additional, De Canal, Gabriella, additional, Iurlo, Alessandra, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2019
Full Text
View/download PDF

10. Jak-2 and Nfkbia Gene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

Author

Pungolino, Ester, primary, D'adda, Mariella, additional, Trojani, Alessandra, additional, Perego, Alessandra, additional, Elena, Chiara, additional, Iurlo, Alessandra, additional, Malato, Simona, additional, Turrini, Mauro, additional, De Canal, Gabriella, additional, Borin, Lorenza, additional, Lodola, Milena, additional, Caramella, Marianna, additional, Artale, Salvatore, additional, Spina, Francesco, additional, Latargia, Maria Luisa, additional, Anghilieri, Michela, additional, Spedini, Pierangelo, additional, Carraro, Mariacristina, additional, Di Camillo, Barbara, additional, Gramegna, Doriana, additional, Pioltelli, Maria Luisa, additional, Rossi, Giuseppe, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2018
Full Text
View/download PDF

11. Nilotinib Deregulates Cell Cycle Checkpoints, ABC Transporters Genes and JAK-STAT Signaling Pathway of CD34+/Lin- Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients after 12 Months of Treatment

Author

Trojani, Alessandra, primary, Pungolino, Ester, additional, Rossi, Giuseppe, additional, D'adda, Mariella, additional, Lodola, Milena, additional, Dal Molin, Alessandra, additional, Baruzzo, Giacomo, additional, Perego, Alessandra, additional, Turrini, Mauro, additional, Elena, Chiara, additional, Borin, Lorenza Maria, additional, Iurlo, Alessandra, additional, Malato, Simona, additional, Spina, Francesco, additional, Latargia, Maria Luisa, additional, Spedini, Pierangelo, additional, Artale, Salvatore, additional, Anghilieri, Michela, additional, Maria Cristina, Carraro, additional, Bucelli, Cristina, additional, De Canal, Gabriella, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2018
Full Text
View/download PDF

13. Nilotinib induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia

Author

Pungolino, Ester, primary, Rossi, Giuseppe, additional, De Canal, Gabriella, additional, Trojani, Alessandra, additional, D'adda, Mariella, additional, Perego, Alessandra, additional, Orlandi, Ester Maria, additional, Lunghi, Francesca, additional, Turrini, Mauro, additional, Borin, Lorenza, additional, Iurlo, Alessandra, additional, Latargia, Maria Luisa, additional, Carraro, Maria Cristina, additional, Spina, Francesco, additional, Lodola, Milena, additional, Artale, Salvatore, additional, Anghilieri, Michela, additional, Spedini, Pierangelo, additional, Cantoni, Silvia, additional, Di Camillo, Barbara, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2018
Full Text
View/download PDF

14. The REL-Protocol PhilosoPhi34 - an Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia (CML) Patients - Confirms Early Clearance of Bone Marrow CD34+/Lin-Ph+ Cells

Author

Pungolino, Ester, primary, De Canal, Gabriella, additional, D'adda, Mariella, additional, Perego, Alessandra, additional, Turrini, Mauro, additional, Orlandi, Ester Maria, additional, Trojani, Alessandra, additional, Borin, Lorenza, additional, Iurlo, Alessandra, additional, Latargia, Maria Luisa, additional, Malato, Simona, additional, Carraro, Maria Cristina, additional, Brusorio, Stefania, additional, Elena, Chiara, additional, Spina, Francesco, additional, Lodola, Milena, additional, Artale, Salvatore, additional, Anghilieri, Michela, additional, Bucelli, Cristina, additional, Pioltelli, Maria Luisa, additional, Cantoni, Silvia, additional, Rossi, Giuseppe, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2016
Full Text
View/download PDF

15. REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data

Author

Pungolino, Ester, primary, Rossi, Giuseppe, additional, Mura, Maria Angela, additional, Perego, Alessandra, additional, Orlandi, Ester Maria, additional, Turrini, Mauro, additional, Borin, Lorenza, additional, Capucci, Maria Adele, additional, Iurlo, Alessandra, additional, Trojani, Alessandra, additional, D'Adda, Mariella, additional, Spina, Francesco, additional, De Canal, Gabriella, additional, Pioltelli, Maria Luisa, additional, Latargia, Maria Luisa, additional, Pauli, Sergio, additional, Elena, Chiara, additional, Brusorio, Stefania, additional, Lanza, Francesco, additional, Malato, Simona, additional, Anghilieri, Michela, additional, Carraro, Maria C, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2015
Full Text
View/download PDF

18. Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment.

Author

Trojani, Alessandra, Pungolino, Ester, Rossi, Giuseppe, D'Adda, Mariella, Lodola, Milena, Di Camillo, Barbara, Perego, Alessandra, Turrini, Mauro, Orlandi, Ester, Borin, Lorenza, Iurlo, Alessandra, Malato, Simona, Spina, Francesco, Latargia, Maria Luisa, Lanza, Francesco, Artale, Salvatore, Anghilieri, Michela, Carraro, Maria Cristina, De Canal, Gabriella, and Morra, Enrica

Subjects
BONE marrow, CHRONIC myeloid leukemia, NILOTINIB, MYELOPROLIFERATIVE neoplasms, GENE expression, PROTEIN-tyrosine kinase inhibitors, DIAGNOSIS, THERAPEUTICS
Abstract

BACKGROUND: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with heterogeneous biological and clinical features. The biomolecular mechanisms of CML response to tyrosine-kinase inhibitors are not fully defined. OBJECTIVE: We undertook a gene expression profiling (GEP) study of selected bone marrow (BM) CD34+/lin- cells of chronic-phase CML patients at diagnosis and after 12 months of TKI nilotinib to investigate molecular signatures characterizing both conditions. METHODS:We selected and counted BM CD34+/lin- cells of 30 CML patients at diagnosis and during 3, 6 and 12 months of first-line nilotinib treatment. GEP was performed between CD34+/lin- cells of patients at diagnosis and the same patients after 12 months of nilotinib. RESULTS: The number of BM CD34+/lin- cells dramatically decreased after 3, 6 and 12 months of nilotinib. GEP detected 264 statistically significant differentially expressed genes at diagnosis vs. 12 months of nilotinib. Functional enrichment analysis revealed groups of genes belonging to 14 pathways differentially active during nilotinib treatment. CONCLUSIONS: In conclusion, lipid, glucose and sphingolipid metabolism, insulin resistance, complement and coagulation, platelet activation, cytoscheleton, cell adhesion, transport, B cell differentiation, RAS-signaling pathway, proliferation, growth factors, and apoptosis were significantly deregulated between CML patients at diagnosis and after 12 months of nilotinib. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

19. Rapid detection of t(15;17)(q24;q21) in acute promyelocytic leukaemia by microwave-assisted fluorescence in situ hybridization.

Author

Soriani, Silvia, Mura, Cinzia, Panico, Anna Rita, Scarpa, Anna Maria, Recchimuzzo, Patrizia, Dadati, Raffaella, Farioli, Renata, De Canal, Gabriella, Mura, Maria Angela, and Cesana, Clara

Abstract

Acute promyelocytic leukaemia (APL) is a hematologic malignancy characterized by the rearrangement of the PML and RARα genes, mostly due to a reciprocal chromosomal translocation t(15;17)(q24;q21). A quick APL diagnosis is essential for starting a prompt suitable therapy. We describe a new rapid diagnostic laboratory approach to detect the PML-RARα rearrangement, which gives clear genetic results within 30 min of hybridization. It combines quick cell harvesting, fluorescence in situ hybridization performed with commercial DNA probe and microwave beams supplied by a domestic microwave oven. Copyright © 2015 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

20. Comparison Between FISH and Immunostimulatory Oligonucleotide-Induced Metaphase Cytogenetics in Previously Untreated CLL: Impact on Prognosis

Author

Tedeschi, Alessandra, primary, Mura, Mariangela, additional, Vismara, Eleonora, additional, Soriani, Silvia, additional, Ricci, Francesca, additional, Roncoroni, Elisa, additional, De Canal, Gabriella, additional, Nichelatti, Michele, additional, Morra, Enrica, additional, and Montillo, Marco, additional

Published
2011
Full Text
View/download PDF

22. Jak-2and Nfkbia Gene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

Author

Pungolino, Ester, D'adda, Mariella, Trojani, Alessandra, Perego, Alessandra, Elena, Chiara, Iurlo, Alessandra, Malato, Simona, Turrini, Mauro, De Canal, Gabriella, Borin, Lorenza, Lodola, Milena, Caramella, Marianna, Artale, Salvatore, Spina, Francesco, Latargia, Maria Luisa, Anghilieri, Michela, Spedini, Pierangelo, Carraro, Mariacristina, Di Camillo, Barbara, Gramegna, Doriana, Pioltelli, Maria Luisa, Rossi, Giuseppe, Morra, Enrica, and Cairoli, Roberto

Abstract

BackgroundTargeted therapy with Tyrosine-Kinase-Inhibitors (TKIs) totally modified the course of treatment of Chronic Myeloid Leukemia (CML). The objectives and the needs of treatment have been modified during the last years and the discontinuation of therapy is now a feasible aim. However, a lot of biological data acquired in the last twenty years, showed that degree and mechanisms of Leukemic Stem Cells (LSCs) clearance during TKI treatment are not clearly established as well as the predictive criteria for a stable and prolonged Treatment Free Remission (TFR). The multicentre, prospective, single-arm PhilosoPhi34 study (EudraCT: 2012-005062-34) was designed by the Rete Ematologica Lombarda (REL), to verify the in-vivo activity and time-course of first-line Nilotinib (NIL) therapy on Bone Marrow (BM) CD34+/lin-Ph+ cells clearance. An exploratory Gene Expression Profiling (GEP) study of CD34+/lin- cells at diagnosis and at 12 months (mos) of treatment, for the first 30 evaluable pts, was included. Preliminary GEP data suggested a correlation between different NFKBIAexpression at diagnosis and at 12 mos and the achievement of a deeper Molecular Response (MR) (Pungolino et al, AJH 2018).

Published
2018
Full Text
View/download PDF

23. Gene Expression Profiling and Cellularity of Bone Marrow CD34+/Lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia at Diagnosis Vs. 12 Months of First-Line Nilotinib Treatment

Author

Trojani, Alessandra, Pungolino, Ester, Rossi, Giuseppe, D'Adda, Mariella, Lodola, Milena, Di Camillo, Barbara, Perego, Alessandra, Turrini, Mauro, Orlandi, Ester Maria, Borin, Lorenza Maria, Iurlo, Alessandra, Malato, Simona, Spina, Francesco, Latargia, Maria Luisa, Lanza, Francesco, Artale, Salvatore, Anghilieri, Michela, Maria Cristina, Carraro, Bucelli, Cristina, De Canal, Gabriella, Morra, Enrica, and Cairoli, Roberto

Abstract

Introduction:Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with heterogeneous biological and clinical features. The biomolecular mechanisms of CML response to tyrosine-kinase inhibitors (TKI) are not fully defined. Despite the TKI nilotinib being a very effective drug for the treatment of CML, drug resistance can emerge. In the contest of the REL-PhilosoPhi34 study (EudraCT: 2012-005062-34) on behalf of the Rete Ematologica Lombarda, we undertook gene expression profiling (GEP) of selected bone marrow (BM) CD34+/lin- cells of 30 patients with CP-CML at diagnosis vs. the same patients after 12 months of nilotinib treatment to investigate molecular signatures characterizing both conditions.

Published
2017
Full Text
View/download PDF

24. BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases.

Author

Carbo-Meix A, Guijarro F, Wang L, Grau M, Royo R, Frigola G, Playa-Albinyana H, Buhler MM, Clot G, Duran-Ferrer M, Lu J, Granada I, Baptista MJ, Navarro JT, Espinet B, Puiggros A, Tapia G, Bandiera L, De Canal G, Bonoldi E, Climent F, Ribera-Cortada I, Fernandez-Caballero M, De la Banda E, Do Nascimento J, Pineda A, Vela D, Rozman M, Aymerich M, Syrykh C, Brousset P, Perera M, Yanez L, Ortin JX, Tuset E, Zenz T, Cook JR, Swerdlow SH, Martin-Subero JI, Colomer D, Matutes E, Bea S, Costa D, Nadeu F, and Campo E

Subjects
Humans, In Situ Hybridization, Fluorescence, Translocation, Genetic, Gene Rearrangement, Immunoglobulin Heavy Chains genetics, Chromosomes, Human, Pair 14 genetics, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Lymphoma, Large B-Cell, Diffuse genetics
Abstract

The t(14;19)(q32;q13) often juxtaposes BCL3 with immunoglobulin heavy chain (IGH) resulting in overexpression of the gene. In contrast to other oncogenic translocations, BCL3 rearrangement (BCL3-R) has been associated with a broad spectrum of lymphoid neoplasms. Here we report an integrative whole-genome sequence, transcriptomic, and DNA methylation analysis of 13 lymphoid neoplasms with BCL3-R. The resolution of the breakpoints at single base-pair revealed that they occur in two clusters at 5' (n=9) and 3' (n=4) regions of BCL3 associated with two different biological and clinical entities. Both breakpoints were mediated by aberrant class switch recombination of the IGH locus. However, the 5' breakpoints (upstream) juxtaposed BCL3 next to an IGH enhancer leading to overexpression of the gene whereas the 3' breakpoints (downstream) positioned BCL3 outside the influence of the IGH and were not associated with its expression. Upstream BCL3-R tumors had unmutated IGHV, trisomy 12, and mutated genes frequently seen in chronic lymphocytic leukemia (CLL) but had an atypical CLL morphology, immunophenotype, DNA methylome, and expression profile that differ from conventional CLL. In contrast, downstream BCL3-R neoplasms were atypical splenic or nodal marginal zone lymphomas (MZL) with mutated IGHV, complex karyotypes and mutated genes typical of MZL. Two of the latter four tumors transformed to a large B-cell lymphoma. We designed a novel fluorescence in situ hybridization assay that recognizes the two different breakpoints and validated these findings in 17 independent tumors. Overall, upstream or downstream breakpoints of BCL3-R are mainly associated with two subtypes of lymphoid neoplasms with different (epi)genomic, expression, and clinicopathological features resembling atypical CLL and MZL, respectively.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results